Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADRX-0405 |
| Synonyms | |
| Therapy Description |
ADRX-0405 is an antibody-drug conjugate (ADC) comprising an antibody targeting STEAP1 linked to a topoisomerase I inhibitor, which potentially induces cytotoxicity in STEAP1-expressing tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1159). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADRX-0405 | ADRX 0405|ADRX0405 | ADRX-0405 is an antibody-drug conjugate (ADC) comprising an antibody targeting STEAP1 linked to a topoisomerase I inhibitor, which potentially induces cytotoxicity in STEAP1-expressing tumor cells and inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1159). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06710379 | Phase I | ADRX-0405 | A Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors | Recruiting | USA | 0 |